Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway.
Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
BMC Cardiovasc Disord. 2021 Jan 21;21(1):44. doi: 10.1186/s12872-021-01866-1.
Adherence to clinical practice guidelines for coronary heart disease (CHD) reduces morbidity, mortality and treatment costs. We aimed to describe and compare adherence to prescription guidelines for persons with CHD, and explore its association with treatment goal achievement.
We included all participants reporting myocardial infarction, angina, percutaneous coronary intervention and/or coronary artery bypass surgery in the seventh wave of the Tromsø Study (2015-2016, n = 1483). Medication use and treatment goal measures (blood pressure, low-density lipoprotein (LDL)-cholesterol and HbA1c) were compared to clinical practice guidelines on secondary CHD prevention. Propensity score matched logistic regression was used to assess the association between the use of antihypertensive drugs and achievement of treatment goal for blood pressure, and the use of lipid-lowering drugs (LLDs) and achievement of treatment goal for LDL-cholesterol.
The prevalence of pharmacological CHD treatment was 76% for LLDs, 72% for antihypertensive drugs and 66% for acetylsalicylic acid. The blood pressure goal (< 140/90 mmHg, < 140/80 mmHg if diabetic) was achieved by 58% and the LDL-cholesterol goal (< 1.8 mmol/l or < 70 mg/dL) by 9%. There was a strong association between using LLDs and achieving the treatment goal for LDL-cholesterol (OR 14.0, 95% CI 3.6-54.7), but not between using antihypertensive drugs and blood pressure goal achievement (OR 1.4, 95% CI 0.7-2.7).
Treatment goal achievement of LDL-cholesterol and blood pressure was low, despite the relatively high use of LLDs and antihypertensive drugs. Further research is needed to find the proper actions to increase achievement of the treatment goals.
遵循冠心病(CHD)临床实践指南可降低发病率、死亡率和治疗成本。我们旨在描述和比较 CHD 患者的处方指南遵循情况,并探讨其与治疗目标实现的关系。
我们纳入了 Tromsø 研究第七波(2015-2016 年)中报告心肌梗死、心绞痛、经皮冠状动脉介入治疗和/或冠状动脉旁路移植术的所有参与者(n=1483)。将药物使用和治疗目标测量值(血压、低密度脂蛋白(LDL)-胆固醇和 HbA1c)与二级 CHD 预防临床实践指南进行比较。采用倾向评分匹配的逻辑回归评估抗高血压药物使用与血压治疗目标的关系,以及降脂药物(LLD)的使用与 LDL-胆固醇治疗目标的关系。
LLD、抗高血压药物和乙酰水杨酸的药物性 CHD 治疗患病率分别为 76%、72%和 66%。血压目标(<140/90mmHg,糖尿病患者<140/80mmHg)的达标率为 58%,LDL-胆固醇目标(<1.8mmol/l 或<70mg/dL)的达标率为 9%。使用 LLD 与 LDL-胆固醇治疗目标达标之间存在很强的关联(OR 14.0,95%CI 3.6-54.7),但使用抗高血压药物与血压目标达标之间没有关联(OR 1.4,95%CI 0.7-2.7)。
尽管 LDL-胆固醇和血压的降脂药物和降压药物使用相对较高,但 LDL-胆固醇和血压的治疗目标达标率较低。需要进一步研究以找到提高治疗目标达标率的适当措施。